MILAN (Reuters) – Italian vaccine vial maker Stevanato on Tuesday said it expected double-digit growth for revenue and core profits this year after beating its forecast for 2021 financial results. The family-controlled group, which listed on the New York Stock Exchange in July, said it expected sales to be between 935-845 million euros this year. Last year revenue rose 27.5% to reach the record level of 844 million euros ($924 million), beating the group’s guidance thanks to products related to COVID-19 and high value solutions. The 2021 adjusted core profit reached 218 million euros, the comp…